The Icelandic founder mutation BRCA2 999del5: analysis of expression

Breast Cancer Research

Volumn 6, Issue 4, 2004, Pages

  Mikaelsdottir, Evgenia K ^a,b   Valgeirsdottir, Sigridur ^c   Eyfjord, Jorunn E ^a,b   Rafnar, Thorunn ^c  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c DECODE GENETICS   (Iceland)

Author keywords

BRCA2; BRCA2 999del5; gene expression; haploinsufficiency; Iceland

Indexed keywords

ACETYLCYSTEINE; BRCA2 PROTEIN; CYSTEINE PROTEINASE; DRUG DERIVATIVE; LACTACYSTIN; MESSENGER RNA; MULTIENZYME COMPLEX; PROTEASOME; RNA; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FOUNDER EFFECT; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; HUMAN; ICELAND; METABOLISM; METHODOLOGY; MOLECULAR WEIGHT; MUTATION; TUMOR SUPPRESSOR GENE;

ACETYLCYSTEINE; ANIMALS; BRCA2 PROTEIN; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; CYSTEINE ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FOUNDER EFFECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA2; HETEROZYGOTE; HUMANS; ICELAND; MOLECULAR WEIGHT; MULTIENZYME COMPLEXES; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE DELETION; TRANSCRIPTION FACTORS;

EID: 7044264728     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr785     Document Type: Article

References (21)

1. P.L. Welcsh M.C. King BRCA1 and BRCA2 and the genetics of breast and ovarian cancer Hum Mol Genet 2001 10 705 713 1:CAS:528:DC%2BD3MXjt1ajsb8%3D 10.1093/hmg/10.7.705 11257103
2. B.H. Spain C.J. Larson L.S. Shihabuddin F.H. Gage I.M. Verma Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations Proc Natl Acad Sci USA 1999 96 13920 13925 1:CAS:528:DyaK1MXns1Oqtbs%3D 10.1073/pnas.96.24.13920 10570174 24166
3. S. Fan R. Yuan Y.X. Ma Q. Meng I.D. Goldberg E.M. Rosen Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1 Oncogene 2001 20 8215 8235 1:CAS:528:DC%2BD38XjslKgsQ%3D%3D 10.1038/sj.onc.1205033 11781837
4. M.A. Brown H. Nicolai K. Howe T. Katagiri E.-N. Lalani El-N K.J. Simpson N.W. Manning A. Deans P. Chen K.K. Khanna M.R. Wati B.L. Griffiths C.F. Xu G.W. Stamp E. Solomon Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice Transgenic Res 2002 11 467 478 1:CAS:528:DC%2BD38XntlSjurc%3D 10.1023/A:1020348025139 12437078
5. V. Sylvain S. Lafarge Y.J. Bignon Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line Int J Oncol 2002 20 845 853 1:CAS:528:DC%2BD38XislOqs74%3D 11894135
6. J.T. Mendell H.C. Dietz When the message goes awry: disease-producing mutations that influence mRNA content and performance Cell 2001 107 411 414 1:CAS:528:DC%2BD3MXovVCnsr0%3D 10.1016/S0092-8674(01)00583-9 11719181
7. D. Thompson D. Easton Variation in cancer risks, by mutation position, in BRCA2 mutation carriers Am J Hum Genet 2001 68 410 419 1:CAS:528:DC%2BD3MXhtl2lsLs%3D 10.1086/318181 11170890 1235274
8. Consortium SNIBB BRCA1 and BRCA2 mutations in Scotland and Northern Ireland Br J Cancer 2003 88 1256 1262 10.1038/sj.bjc.6600840
9. H. Tulinius G.H. Olafsdottir H. Sigvaldason A. Arason R.B. Barkardottir V. Egilsson H.M. Ogmundsdottir L. Tryggvadottir S. Gudlaugsdottir J.E. Eyfjord The effect of a single BRCA2 mutation on cancer in Iceland J Med Genet 2002 39 457 462 1:CAS:528:DC%2BD38Xmtlyktr8%3D 10.1136/jmg.39.7.457 12114473 1735175
10. S.V. Tavtigian J. Simard J. Rommens F. Couch D. Shattuck-Eidens S. Neuhausen S. Merajver S. Thorlacius K. Offit D. Stoppa-Lyonnet C. Belanger R. Bell S. Berry R. Bogden Q. Chen T. Davis M. Dumont C. Frye T. Hattier S. Jammulapati T. Janecki P. Jiang R. Kehrer J.-F. Leblanc J.T. Mitchell J. McArthur-Morrison K. Nguyen Y. Peng C. Samson M. Schroeder S.C. Snyder L. Steele M. Stringfellow C. Stroup B. Swedlund J. Swensen D. Teng A. Thomas T. Tran T. Tran M. Tranchant J. Weaver-Feldhaus A.K.C. Wong H. Shizuya J.E. Eyfjord L. Cannon-Albright F. Labrie M.H. Skolnick B. Weber A. Kamb D.E. Goldgar The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds Nat Genet 1996 12 333 337 1:CAS:528:DyaK28XhvVSgtbk%3D 10.1038/ng0396-333 8589730
11. S. Thorlacius G. Olafsdottir L. Tryggvadottir S. Neuhausen J.G. Jonasson S.V. Tavtigian H. Tulinius H.M. Ogmundsdottir J.E. Eyfjord A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes Nat Genet 1996 13 117 119 1:CAS:528:DyaK28XksVWgu74%3D 10.1038/ng0596-117 8673089
12. S. Thorlacius S. Sigurdsson H. Bjarnadottir G. Olafsdottir J.G. Jonasson L. Tryggvadottir H. Tulinius J.E. Eyfjord Study of a single BRCA2 mutation with high carrier frequency in a small population Am J Hum Genet 1997 60 1079 1084 1:STN:280:DyaK2s3psVequw%3D%3D 9150155 1712443
13. S. Thorlacius J.P. Struewing P. Hartge G.H. Olafsdottir H. Sigvaldason L. Tryggvadottir S. Wacholder H. Tulinius J.E. Eyfjord Population-based study of risk of breast cancer in carriers of BRCA2 mutation Lancet 1998 352 1337 1339 1:STN:280:DyaK1M%2FhslamtA%3D%3D 10.1016/S0140-6736(98)03300-5 9802270
14. R. Losson F. Lacroute Interference of nonsense mutations with eukaryotic messenger RNA stability Proc Natl Acad Sci USA 1979 76 5134 5137 1:CAS:528:DyaL3cXjtVGm 10.1073/pnas.76.10.5134 388431 413094
15. T. Schell A.E. Kulozik M.W. Hentze Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway [review] Genome Biol 2002 3 1006 10.1186/gb-2002-3-3-reviews1006 http://genomebiology.com/2002/3/3/reviews/1006
16. H. Ruffner C.A. Joazeiro D. Hemmati T. Hunter I.M. Verma Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity Proc Natl Acad Sci USA 2001 98 5134 5139 1:CAS:528:DC%2BD3MXjt1Ons7s%3D 10.1073/pnas.081068398 11320250 33176
17. S.A. Gayther J. Mangion P. Russell S. Seal R. Barfoot B.A. Ponder M.R. Stratton D. Easton Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene Nat Genet 1997 15 103 105 1:CAS:528:DyaK2sXjsFKjsQ%3D%3D 10.1038/ng0197-103 8988179
18. R. Mizuta J.M. LaSalle H.L. Cheng A. Shinohara H. Ogawa N. Copeland N.A. Jenkins M. Lalande F.W. Alt RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein Proc Natl Acad Sci USA 1997 94 6927 6932 1:CAS:528:DyaK2sXktF2qsro%3D 10.1073/pnas.94.13.6927 9192668 21261
19. A.K. Wong R. Pero P.A. Ormonde S.V. Tavtigian P.L. Bartel RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2 J Biol Chem 1997 272 31941 31944 1:CAS:528:DyaK1cXis1CmtA%3D%3D 10.1074/jbc.272.51.31941 9405383
20. D. Gorlich I.W. Mattaj Nucleocytoplasmic transport Science 1996 271 1513 1518 1:CAS:528:DyaK28XhslSjsL0%3D 10.1126/science.271.5255.1513 8599106
21. C.J. Sarkisian S.R. Master L.J. Huber S.I. Ha L.A. Chodosh Analysis of murine Brca2 reveals conservation of protein–protein interactions but differences in nuclear localization signals J Biol Chem 2001 276 37640 37648 1:CAS:528:DC%2BD3MXns1eksbg%3D 10.1074/jbc.M106281200 11477095